株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

癌免疫アッセイの世界市場 (〜2024年):免疫測定・フローサイトメトリー・PCR・次世代シーケンシング

Immuno Oncology Assays Market by Product (Consumables, Software), Technology (Immunoassay, Flow Cytometry, PCR, Next Generation Sequencing), Indication (Lung Cancer, Colorectal Cancer), Application - Global Forecast to 2024

発行 MarketsandMarkets 商品コード 790813
出版日 ページ情報 英文 109 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.75円で換算しております。
Back to Top
癌免疫アッセイの世界市場 (〜2024年):免疫測定・フローサイトメトリー・PCR・次世代シーケンシング Immuno Oncology Assays Market by Product (Consumables, Software), Technology (Immunoassay, Flow Cytometry, PCR, Next Generation Sequencing), Indication (Lung Cancer, Colorectal Cancer), Application - Global Forecast to 2024
出版日: 2019年02月14日 ページ情報: 英文 109 Pages
概要

癌免疫アッセイの市場は予測期間中12.7%のCAGR (年間複合成長率) で推移し、2018年の29億米ドルから、2024年には59億米ドルの規模に成長すると予測されています。従来の療法に勝る標的療法の導入拡大、モノクローナル抗体需要の拡大などの要因が同市場の成長を推進しています。しかし一方で、免疫療法の高コスト性、製品開発サイクルにおける高い脱落率などの要因が同市場のさらなる成長の障壁となっています。

当レポートでは、世界の癌免疫アッセイの市場を調査し、市場および技術の概要、市場成長への各種影響因子および市場機会の分析、製品・技術・適応症・用途・地域別の動向と市場規模の推移と予測、競合環境、主要企業のプロファイルなどをまとめています。

FIGURE 11 IMMUNO-ONCOLOGY ASSAYS MARKET

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 成長推進因子
    • 成長抑制因子
    • 市場機会
    • 課題

第6章 癌免疫アッセイ市場の分析・予測:製品別

  • イントロダクション
  • 消耗品
  • ソフトウェア

第7章 癌免疫アッセイ市場の分析・予測:技術別

  • イントロダクション
  • PCR
  • 免疫測定
  • 次世代シーケンシング
  • フローサイトメトリー
  • その他

第8章 癌免疫アッセイ市場の分析・予測:適応症別

  • イントロダクション
  • 肺癌
  • 大腸癌
  • 黒色腫
  • 膀胱癌
  • その他

第9章 癌免疫アッセイ市場の分析・予測:用途別

  • イントロダクション
  • 研究用途
  • 臨床用途

第10章 癌免疫アッセイ市場の分析・予測:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
  • アジア太平洋
  • その他

第11章 競合環境

  • 概要
  • ベンダーベンチマーキング
  • 競合リーダーシップマッピング
  • 市場ランキング
  • 競合状況・動向
    • 提携
    • 製品の投入
    • 買収
    • 拡張

第12章 企業プロファイル

  • THERMO FISHER SCIENTIFIC, INC.
  • ROCHE DIAGNOSTICS
  • AGILENT TECHNOLOGIES, INC.
  • ILLUMINA, INC.
  • NANOSTRING TECHNOLOGIES, INC.
  • SARTORIUS AG
  • FOUNDATION MEDICINE
  • HTG MOLECULAR DIAGNOSTICS, INC.
  • QIAGEN
  • MERCK
  • PERKINELMER

第13章 付録

図表

LIST OF TABLES

  • TABLE 1: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT, 2016-2024 (USD MILLION)
  • TABLE 2: IMMUNO-ONCOLOGY ASSAYS MARKET FOR CONSUMABLES, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 3: NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET FOR CONSUMABLES, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 4: IMMUNO-ONCOLOGY ASSAYS MARKET FOR SOFTWARE, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 5: NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET FOR SOFTWARE, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 6: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2016-2024 (USD MILLION)
  • TABLE 7: IMMUNO-ONCOLOGY ASSAYS MARKET FOR PCR, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 8: NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET FOR PCR, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 9: IMMUNO-ONCOLOGY ASSAYS MARKET FOR IMMUNOASSAY, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 10: NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET FOR IMMUNOASSAY, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 11: IMMUNO-ONCOLOGY ASSAYS MARKET FOR NGS, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 12: NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET FOR NGS, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 13: IMMUNO-ONCOLOGY ASSAYS MARKET FOR FLOW CYTOMETRY, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 14: NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 15: IMMUNO-ONCOLOGY ASSAYS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 16: NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 17: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2016-2024 (USD MILLION)
  • TABLE 18: IMMUNO-ONCOLOGY ASSAYS MARKET FOR LUNG CANCER, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 19: NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET FOR LUNG CANCER, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 20: IMMUN0-ONCOLOGY ASSAYS MARKET FOR COLORECTAL CANCER, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 21: NORTH AMERICA: IMMUN0-ONCOLOGY ASSAYS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 22: IMMUN0-ONCOLOGY ASSAYS MARKET FOR MELANOMA, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 23: NORTH AMERICA: IMMUN0-ONCOLOGY ASSAYS MARKET FOR MELANOMA, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 24: IMMUN0-ONCOLOGY ASSAYS MARKET FOR BLADDER CANCER, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 25: NORTH AMERICA: IMMUN0-ONCOLOGY ASSAYS MARKET FOR BLADDER CANCER, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 26: IMMUNO-ONCOLOGY ASSAYS MARKET FOR OTHER CANCERS, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 27: NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET FOR OTHER CANCERS, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 28: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2016-2024 (USD MILLION)
  • TABLE 29: IMMUNO-ONCOLOGY ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 30: NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 31: IMMUNO-ONCOLOGY ASSAYS MARKET FOR APPLICATIONS, BY CLINICAL DIAGNOSTICS, 2016-2024 (USD MILLION)
  • TABLE 32: NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 33: IMMUNO-ONCOLOGY ASSAYS MARKET, BY REGION, 2016-2024 (USD MILLION)
  • TABLE 34: NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY COUNTRY, 2016-2024 (USD MILLION)
  • TABLE 35: NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT, 2016-2024 (USD MILLION)
  • TABLE 36: NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2016-2024 (USD MILLION)
  • TABLE 37: NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2016-2024 (USD MILLION)
  • TABLE 38: NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2016-2024 (USD MILLION)
  • TABLE 39: US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT, 2016-2024 (USD MILLION)
  • TABLE 40: US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2016-2024 (USD MILLION)
  • TABLE 41: US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2016-2024 (USD MILLION)
  • TABLE 42: US: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2016-2024 (USD MILLION)
  • TABLE 43: CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT, 2016-2024 (USD MILLION)
  • TABLE 44: CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2016-2024 (USD MILLION)
  • TABLE 45: CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2016-2024 (USD MILLION)
  • TABLE 46: CANADA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2016-2024 (USD MILLION)
  • TABLE 47: EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT, 2016-2024 (USD MILLION)
  • TABLE 48: EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2016-2024 (USD MILLION)
  • TABLE 49: EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2016-2024 (USD MILLION)
  • TABLE 50: EUROPE: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2016-2024 (USD MILLION)
  • TABLE 51: APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT, 2016-2024 (USD MILLION)
  • TABLE 52: APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2016-2024 (USD MILLION)
  • TABLE 53: APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2016-2024 (USD MILLION)
  • TABLE 54: APAC: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2016-2024 (USD MILLION)
  • TABLE 55: ROW: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT, 2016-2024 (USD MILLION)
  • TABLE 56: ROW: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2016-2024 (USD MILLION)
  • TABLE 57: ROW: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2016-2024 (USD MILLION)
  • TABLE 58: ROW: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2016-2024 (USD MILLION)
  • TABLE 59: VENDOR BENCHMARKING BY GROWTH STRATEGY
  • TABLE 60: COLLABORATIONS, 2016-2018
  • TABLE 61: PRODUCT LAUNCHES, 2016-2018
  • TABLE 62: ACQUISITIONS, 2016-2018
  • TABLE 63: EXPANSIONS, 2015 TO 2018

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 4: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 5: DATA TRIANGULATION
  • FIGURE 6: IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION, 2018 VS. 2024 (USD MILLION)
  • FIGURE 7: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT, 2018 VS. 2024 (USD MILLION)
  • FIGURE 8: IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION, 2018 VS. 2024 (USD MILLION)
  • FIGURE 9: IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY, 2018 VS. 2024 (USD MILLION)
  • FIGURE 10: GEOGRAPHICAL SNAPSHOT OF THE IMMUNO-ONCOLOGY ASSAYS MARKET
  • FIGURE 11: INCREASING ADOPTION OF TARGETED THERAPY OVER TRADITIONAL THERAPY IS A KEY DRIVER FOR THE IMMUNO-ONCOLOGY ASSAYS MARKET
  • FIGURE 12: CONSUMABLES SEGMENT TO ACCOUNT FOR LARGEST SHARE IN NORTH AMERICAN IMMUNO-ONCOLOGY ASSAYS MARKET
  • FIGURE 13: RESEARCH APPLICATIONS TO CONTINUE TO DOMINATE THE IMMUNO-ONCOLOGY ASSAYS MARKET IN 2024
  • FIGURE 14: PCR SEGMENT WILL CONTINUE TO DOMINATE THE IMMUNO-ONCOLOGY ASSAYS MARKET IN 2024
  • FIGURE 15: APAC WILL BE THE FASTEST-GROWING MARKET FROM 2018 TO 2024
  • FIGURE 16: IMMUNO-ONCOLOGY ASSAYS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
  • FIGURE 17: NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET SNAPSHOT
  • FIGURE 18: ASIA PACIFIC: IMMUNO-ONCOLOGY ASSAYS MARKET SNAPSHOT
  • FIGURE 19: IMMUNO-ONCOLOGY ASSAYS MARKET (GLOBAL), COMPETITIVE LEADERSHIP MAPPING, 2017
  • FIGURE 20: RANK OF COMPANIES IN THE GLOBAL IMMUNO-ONCOLOGY ASSAYS MARKET, 2017
  • FIGURE 21: THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2017)
  • FIGURE 22: ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2017)
  • FIGURE 23: AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2017)
  • FIGURE 24: ILLUMINA: COMPANY SNAPSHOT (2017)
  • FIGURE 25: NANOSTRING TECHNOLOGIES: COMPANY SNAPSHOT (2017)
  • FIGURE 26: SARTORIUS AG: COMPANY SNAPSHOT (2017)
  • FIGURE 27: HTG MOLECULAR DIAGNOSTICS: COMPANY SNAPSHOT (2017)
  • FIGURE 28: QIAGEN: COMPANY SNAPSHOT (2017)
  • FIGURE 29: MERCK: COMPANY SNAPSHOT (2017)
  • FIGURE 30: PERKINELMER: COMPANY SNAPSHOT (2017)
目次
Product Code: MD 6896

"The increasing adoption of targeted therapy over traditional therapy is expected to drive the overall growth of the immuno-oncology assays market."

The immuno-oncology assays market is expected to grow from USD 2.9 billion in 2018 to USD 5.9 billion by 2024, at a CAGR of 12.7% during the forecast period. The immuno-oncology assays market is driven primarily by factors such as the increasing adoption of targeted therapy over traditional therapy and the increasing demand for mAbs. However, the high cost of immunotherapy treatment and the high attrition rate in the product development cycle are the major factors that are expected to restrain the growth of this market during the forecast period.

"The lung cancer segment is expected to grow at the highest CAGR during the forecast period."

Based on indication, the immuno-oncology assays market is segmented into lung cancer, colorectal cancer, melanoma, bladder cancer, and other cancers. The lung cancer segment is expected to be the fastest-growing segment during the forecast period, as major players are focusing on immuno-oncology research for lung cancer owing to its increasing incidence.

"Asia Pacific projected to grow at the highest CAGR during the forecast period."

The Asia Pacific is projected to record the highest growth rate during the forecast period. Factors such as growing number of CROs in the region, increasing awareness about early detection of cancer, and the shift of manufacturers' and suppliers' focus from developed economies to emerging economies, such as India and China are driving the growth of this regional segment.

In-depth interviews were conducted with Chief Executive Officers (CEOs), marketing directors, other innovation and technology directors, and executives from various key organizations operating in the immuno-oncology assays market.

  • By Company Type: Tier 1: 18%, Tier 2: 39%, and Tier 3: 43%
  • By Designation: C-level Executives: 25%, Directors: 20%, and Others: 55%
  • By Region: North America: 40%, Europe: 27%, APAC: 20%, and RoW: 13%

The immuno-oncology assays market comprises major providers such as Thermo Fischer Scientific (US), Roche Diagnostics (Switzerland), Agilent Technologies (US), and Illumina (US). The study includes an in-depth competitive analysis of these key players in the immuno-oncology assays market, along with their company profiles, recent developments, and key market strategies.

Research Coverage:

The market study covers the immuno-oncology assays market across various segments. It aims at estimating the market size and the growth potential of this market across different segments, on the basis of product, technology, application, indication, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall immuno-oncology assays market and its subsegments. This report will help the stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies. The report will also help the stakeholders to understand the pulse of the market and provide information on key market drivers, restraints, and opportunities.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS COVERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. PRIMARY DATA
    • 2.1.1. KEY DATA FROM PRIMARY SOURCES
    • 2.1.2. KEY INDUSTRY INSIGHTS
  • 2.2. SECONDARY DATA
    • 2.2.1. KEY DATA FROM SECONDARY SOURCES
  • 2.3. MARKET SIZE ESTIMATION
  • 2.4. MARKET BREAKDOWN AND DATA TRIANGULATION
    • 2.4.1. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. IMMUNO-ONCOLOGY ASSAYS: MARKET OVERVIEW
  • 4.2. NORTH AMERICA: IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT AND COUNTRY (2018)
  • 4.3. IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION (2018 VS. 2024)
  • 4.4. IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY (2018 VS. 2024)
  • 4.5. GEOGRAPHICAL SNAPSHOT OF THE IMMUNO-ONCOLOGY ASSAYS MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Rising incidence of cancer and increasing adoption of targeted therapy
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. Unfavorable regulatory and reimbursement scenario
      • 5.2.2.2. High amount of capital investments and low benefit-cost ratio
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Companion diagnostics

6. IMMUNO-ONCOLOGY ASSAYS MARKET, BY PRODUCT

  • 6.1. INTRODUCTION
  • 6.2. CONSUMABLES
    • 6.2.1. CONSUMABLES SEGMENT WILL CONTINUE TO DOMINATE THE IMMUNO-ONCOLOGY ASSAYS MARKET DURING THE FORECAST PERIOD
  • 6.3. SOFTWARE
    • 6.3.1. THE NEED TO DELIVER ACCURATE AND TIMELY ANALYSIS OF DIAGNOSTIC TESTS HAS RESULTED IN THE INCREASED ADOPTION OF SOFTWARE

7. IMMUNO-ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY

  • 7.1. INTRODUCTION
  • 7.2. PCR
    • 7.2.1. EMERGENCE OF ADVANCED PCR TECHNOLOGIES TO SUPPORT MARKET GROWTH
  • 7.3. IMMUNOASSAY
    • 7.3.1. IMMUNOASSAYS HAVE THE POTENTIAL TO REDUCE CANCER MORTALITY RATE BY FACILITATING THE DIAGNOSIS OF CANCER IN THE EARLY STAGE
  • 7.4. NGS
    • 7.4.1. NGS SEGMENT TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • 7.5. FLOW CYTOMETRY
    • 7.5.1. FLOW CYTOMETRY PLAYS A CRITICAL ROLE IN CLINICAL RESEARCH STUDIES
  • 7.6. OTHER TECHNOLOGIES

8. IMMUNO-ONCOLOGY ASSAYS MARKET, BY INDICATION

  • 8.1. INTRODUCTION
  • 8.2. LUNG CANCER
    • 8.2.1. INCREASING R&D ACTIVITIES ON LUNG IMMUNO-ONCOLOGY ASSAYS IS A KEY MARKET DRIVER
  • 8.3. COLORECTAL CANCER
    • 8.3.1. HIGH SUCCESS RATE OF IMMUNO-ONCOLOGY ASSAYS IN CRC TREATMENT DECISIONS TO DRIVE MARKET GROWTH
  • 8.4. MELANOMA
    • 8.4.1. GROWING CASES OF MELANOMA TO DRIVE MARKET GROWTH
  • 8.5. BLADDER CANCER
    • 8.5.1. BLADDER CANCER SEGMENT TO WITNESS SLOWER GROWTH OWING TO THE LIMITED ADOPTION OF IMMUNO-ONCOLOGY ASSAYS
  • 8.6. OTHER CANCERS

9. IMMUNO-ONCOLOGY ASSAYS MARKET, BY APPLICATION

  • 9.1. INTRODUCTION
  • 9.2. RESEARCH APPLICATIONS
    • 9.2.1. RISING PROMINENCE OF BIOMARKER-BASED DRUG DEVELOPMENT AND CLINICAL TRIALS TO DRIVE THE RESEARCH APPLICATIONS MARKET
  • 9.3. CLINICAL DIAGNOSTICS
    • 9.3.1. BENEFITS OF IMMUNO-ONCOLOGY ASSAYS ARE DRIVING ITS ADOPTION IN CLINICAL DIAGNOSTICS

10. IMMUNO-ONCOLOGY ASSAYS MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. US
      • 10.2.1.1. Increasing demand for immunotherapy medicine forms a key driver of market growth in the US
    • 10.2.2. CANADA
      • 10.2.2.1. High burden of cancer to drive the demand for immuno-oncology assays
  • 10.3. EUROPE
    • 10.3.1. RISING FOCUS ON BIOMARKER DEVELOPMENT IN SEVERAL EU COUNTRIES TO SUPPORT MARKET GROWTH
  • 10.4. ASIA PACIFIC
    • 10.4.1. INCREASING DEMAND FOR BETTER HEALTHCARE SERVICES IN DEVELOPING ECONOMIES WILL CONTRIBUTE TO MARKET GROWTH
  • 10.5. REST OF THE WORLD

11. COMPETITIVE LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. VENDOR BENCHMARKING
  • 11.3. COMPETITIVE LEADERSHIP MAPPING
    • 11.3.1. VISIONARY LEADERS
    • 11.3.2. INNOVATORS
    • 11.3.3. DYNAMIC DIFFERENTIATORS
    • 11.3.4. EMERGING COMPANIES
  • 11.4. MARKET RANKING ANALYSIS, 2017
  • 11.5. COMPETITIVE SITUATION AND TRENDS
    • 11.5.1. COLLABORATIONS
    • 11.5.2. PRODUCT LAUNCHES
    • 11.5.3. ACQUISITIONS
    • 11.5.4. EXPANSIONS

12. COMPANY PROFILES (Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

  • 12.1. THERMO FISHER SCIENTIFIC, INC.
  • 12.2. ROCHE DIAGNOSTICS
  • 12.3. AGILENT TECHNOLOGIES, INC.
  • 12.4. ILLUMINA, INC.
  • 12.5. NANOSTRING TECHNOLOGIES, INC.
  • 12.6. SARTORIUS AG
  • 12.7. FOUNDATION MEDICINE
  • 12.8. HTG MOLECULAR DIAGNOSTICS, INC.
  • 12.9. QIAGEN
  • 12.10. MERCK
  • 12.11. PERKINELMER

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. INSIGHTS OF INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4. AVAILABLE CUSTOMIZATIONS
  • 13.5. RELATED REPORTS
  • 13.6. AUTHOR DETAILS
Back to Top